Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.GlaxoSmithKline (GSK) and The Texas A&M University System have announced the US Department of Health and Human Services' (DHHS) clearance for the establishment of TAMUS influenza vaccine facility in Bryan-College Station, Texas.
Subscribe to our email newsletter
The $91m influenza-vaccines manufacturing plant will be the anchor of the Center for Innovation in Advanced Development and Manufacturing (CIADM).
Texas Governor Rick Perry said, "The Texas A&M Center, anchored by this facility, is expected to bring more than $41 billion in expenditures within the State of Texas over the next 25 years, and will add more than 6,800 direct and related jobs to Texas."
Once constructed and operational, TAMUS influenza vaccines manufacturing center will manufacture GSK’s influenza vaccine based on a proprietary cell-culture line, EB66, to protect the nation against global pandemics.
Packaging, inspection and distribution oeprations of the influenza vaccines manufactured at the center will be carried out by GSK’s facility in Marietta, Pennsylvania.
GSK Vaccines senior vice president Antoon Loomans said, "In Texas A&M we have found a partner with a rich tradition of service, and with pioneering technologies that will benefit the entire pharmaceutical industry in making vaccines available and accessible to all in need."
The center will be capable of supplying 50 million doses of pandemic influenza vaccine within four months of an outbreak.
The Texas A&M System strategic initiatives vice chancellor Dr. Brett Giroir along with a core team of A&M experts in biotechnology, infectious diseases, facilities planning and construction, federal acquisitions/contracting, and government affairs will lead the Texas A&M Center for Innovation.